Applications
News & Events
Contact
News Events

2024.03.07

EurekaBio Completes $40 Million Series B+ Financing to Advance EuLV™ Lentiviral Vector Production System

2023.04.18

EurekaBio Facilitating IND Application Filings and Advancing the Commercialization of CGT Drugs

2023.04.03

EurekaBio Bestowed with "CGT Award - Most Innovative Intelligent Manufacturing Equipment Supplier of 2023"

2022.12.29

EurekaBio Clinches the Accolade of “Top 50 Innovative Biotechnology Companies in Guangdong-Hong Kong-Macao Greater Bay Area - Pioneer Enterprise Award”

2022.07.22

EurekaBio and BinDeBio Enter into Strategic Partnership to Jointly Propel the Growth of the Cell Therapy Industry in the Greater Bay Area

2022.12.30

CorreGene and EurekaBio Enter into Strategic Partnership to Expedite Commercialization of TCR Therapy Advancements

2023.05.06

EurekaBio Secures Two Awards of “2023 Future Healthcare VB100”

2023.05.07

A Delegation from the Cell and Gene Therapy Product Regulation Research Committee under the China Society for Drug Regulation Visits EurekaBio for Research and Guidance

2023.03.15

EurekaBio Accredited as a “Specialized and Sophisticated Enterprise that Produces Novel and Unique Products” in Shenzhen
Footer

Our story starts here…..

© 2024 Shenzhen Eureka Biotechnology Co., Limited. Privacy Policy

Viral Vector R&D and Scale-up Solutions

EuLV™ System

Cell Therapy Manufacturing Solutions

CellSep™ PRO

CellSep™ MAX

Applications News & Events Careers About Us

Interdisciplinary Biotechnology R&D Platforms

EuBioX System

Contact